Gut microbiota-derived SCFAs and MetS-related nephropathy

Area of Science:

• Microbiology
• Nephrology
• Metabolic Disorders

Background:

• Metabolic syndrome (MetS) involves complex metabolic abnormalities impacting kidney function.
• Gut microbiota significantly influences host physiology and pathology, including metabolic processes.
• Metabolic disorders can lead to structural and functional renal damage.

Purpose of the Study:

• To review the role of gut microbiota-derived short-chain fatty acids (SCFAs) in metabolic syndrome-related nephropathy.
• To explore SCFAs as a prospective therapeutic strategy for MetS-related kidney damage.

Main Methods:

• Review of existing clinical and animal studies on SCFAs and MetS-related nephropathy.
• Analysis of the mechanisms by which SCFAs influence metabolic processes and inflammation.
• Investigation of SCFA interactions with G protein-coupled receptors (GPRs) and Histone deacetylase activity (HDAC).

Main Results:

• Gut microbiota-derived metabolites, particularly SCFAs, exert anti-inflammatory, antioxidant, and lipid metabolism-improving effects in MetS.
• SCFAs modulate energy metabolism, regulate immune responses, and inhibit oxidative stress and mitochondrial damage.
• Therapeutic studies indicate SCFAs have a significant relationship with MetS-related nephropathy.

Conclusions:

• SCFAs play a crucial role in mitigating kidney damage associated with metabolic syndrome.
• Understanding SCFA mechanisms offers a novel therapeutic avenue for MetS-related nephropathy.
• Further research is needed to fully elucidate SCFA functions in diverse metabolic disorder-induced kidney damage.